Athenex, Inc, a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, has announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of US$11.00 per share. The gross proceeds to Athenex from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be US$110 million. In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 14, 2020, subject to customary closing conditions.
Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili and Bay Area partner Brain Cuneo, with Bay Area associate Phillip Stoup, and New York associates Milo LeDoux and MacLane Taggart.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.